Intravenous products: CW Optics, Inc. announced today the launch of a clinical trial at the Virginia Commonwealth University Health System to investigate the safety and efficacy of ivWatch®, a novel optical device for monitoring intravenous (IV) infusion sites for infiltration. Each year, there are approximately 150 million peripheral IV insertions in the United States and about 3% result in infiltration, or fluid leaks, which can cause pain, skin loss requiring plastic surgery, nerve damage, and amputation of the affected limb.
Currently, there are no devices on the market that continuously monitor infusion sites for infiltration.
The gold standard for infiltration detection is a subjective check by the nurse. The ivWatch® applies CW Optics’ proprietary technology (patent to be issued November, 2010) to monitor signs of infiltration in realtime.